A review of the safety and tolerability of sertindole

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 3, 1998, Pages

  Hale, Anthony S ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Cardiovascular side effects; Extrapyramidal side effects; Safety; Sertindole; Tolerability

Indexed keywords

BENZATROPINE; DIPHENHYDRAMINE; HALOPERIDOL; PROPRANOLOL; SERTINDOLE; TRIHEXYPHENIDYL;

CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FREQUENCY ANALYSIS; HUMAN; HUMAN TISSUE; HYPOKALEMIA; INCIDENCE; LONG QT SYNDROME; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCHIZOPHRENIA; VERTIGO;

EID: 0031798522     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803003-00011     Document Type: Review

References (22)

1. Beasley CM (1997). Letter to the editor: reply. Neuropsychopharmacology 16:163.
2. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
3. Ben-David J, Zipes DP (1993). Arrhythmia octet: torsades de pointes and proarrhythmia. Lancet 341:1578-1582.
4. Daniel D, Schmitz P, Staser J, et al. (1996). Two open-label long-term, safety studies of sertindole [abstract]. In: American Psychiatric Association 149th Annual Meeting, New York. Washington (DC): American Psychiatric Association.
5. Davies MA, Conley RR, Schulz SC, Bell-Delaney J (1991). One-year follow-up of 24 patients in a clinical trial of clozapine. Hosp Comm Psychiatry 42:628-629.
6. Davis JM, Janicak R, Singla A, Sharma RP (1993). Maintenance antipsychotic medication. In: Antipsychotic drugs and their side-effects. Barnes TRE (editor). London: Academic Press. pp. 183-203.
7. Garson A (1993). How to measure Q-T interval: what is normal? Am J Cardiol 72:14B-16B.
8. Hale AS (1993). Will new antipsychotics improve the treatment of schizophrenia? BMJ 307:749-750.
9. Hale AS, Pininiti NR (1995). Critical flicker fusion threshold and anticholinergic effects of chronic antidepressant treatment in remitted depressives. J Psychopharmacol 9:258-266.
10. Hale AS, van der Burgh M, Friberg HH, Wehnert A (1996). Dose ranging study comparing 4 doses of sertindole and 1 dose of haloperidol in schizophrenic patients [abstract]. Eur Neuropsychopharmacol 6 (suppl 3):61.
11. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1985). Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254-258.
12. Kerwin R (1993). Adverse reaction reporting and new antipsychotics. Lancet 342:1440.
13. Lindström E, Eriksson B, Hellgren A, von Knorring L, Eberhard G (1995). Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 17:402-412.
14. Lundbeck Ltd (1997). Serdolect (sertindole) product monograph. Rev Jan 1997. Milton Keynes: Lundbeck Ltd.
15. Marder SR, Meibach RC (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
16. C interval: impact on defining drug effect and low frequency cardiac effect. Am J Cardiol 72:26B-31B.
17. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M (1991). Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48:166-170.
18. Thomas M, Maconochie JG, Fletcher E (1996). The dilemma of the prolonged Q-T interval in early drug studies. Br J Clin Pharmacol 41:77-81.
19. Van Kammen DP, McEvoy KP, Targum SD, Kardatzke D, Seebree TB, Sertindole Study Group (1996). A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia Psychopharmacology 124:168-175.
20. Van PuttenT, Marder SR, Mintz J (1990). A controlled dose comparison of haloperidol in newly administered schizophrenic patients. Arch Gen Psychiatry 47:754-758.
21. Warner JP, Barnes TR, Henry JA (1994). Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93:311-313.
22. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782-791.